Edition:
United States

Syros Pharmaceuticals Inc (SYRS.OQ)

SYRS.OQ on NASDAQ Stock Exchange Global Select Market

12.78USD
4:00pm EDT
Change (% chg)

$-0.25 (-1.92%)
Prev Close
$13.03
Open
$13.13
Day's High
$13.26
Day's Low
$12.77
Volume
50,152
Avg. Vol
67,413
52-wk High
$24.35
52-wk Low
$6.31

Chart for

About

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments... (more)

Overall

Beta: --
Market Cap(Mil.): $426.12
Shares Outstanding(Mil.): 32.58
Dividend: --
Yield (%): --

Financials

  SYRS.OQ Industry Sector
P/E (TTM): -- 29.73 33.88
EPS (TTM): -2.11 -- --
ROI: -64.03 13.68 13.21
ROE: -65.23 15.46 15.18

BRIEF-Syros Pharmaceuticals Reports Q4 Loss Per Share $0.58

* SYROS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT ACCOMPLISHMENTS AND ANTICIPATED MILESTONES

Mar 12 2018

BRIEF-Syros Pharmaceuticals Enters Amendment To Stock Purchase Agreement With Incyte

* SYROS PHARMACEUTICALS -‍ ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING​

Jan 31 2018

BRIEF-Syros Prices Public Offering Of 4.19 Mln Common Shares At $9.55/Share

* SYROS ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING OF COMMON STOCK

Jan 30 2018

BRIEF-Syros Announces Proposed Offering Of Common Stock

* SYROS PHARMACEUTICALS INC - ‍OFFERING TO SELL $40.0 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING​ Source text for Eikon: Further company coverage:

Jan 30 2018

BRIEF-Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement

* INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT

Jan 08 2018

BRIEF-Syros Announces 2018 Strategic Priorities And Expected Milestones

* SYROS ANNOUNCES 2018 STRATEGIC PRIORITIES AND EXPECTED MILESTONES

Jan 08 2018

BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425

* SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS

Jan 02 2018

Earnings vs. Estimates